Analysis finds 33-fold rise in supervised BPC-157 use since 2020
Data firm nference identified 1,039 patients given the unapproved peptide under physician supervision, with no comparator, standard dose or route across the records.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 21 08:58 ETSource: NewsNation
The wire
- 01nference counted 1,039 patients using BPC-157 under a doctor's supervision, a 33-fold increase between 2020 and 2026; among 644 analyzed, clinicians noted improvement in sports injuries, chronic pain and gastrointestinal disorders.
- 02BPC-157 remains FDA-unapproved but has backing from HHS Secretary Robert F. Kennedy Jr., who in July urged an FDA advisory panel to permit pharmacy compounding of it.
- 03Utah's Dr. Flynn McGuire notes there was no placebo or untreated comparator and no standardized indication, formulation, dose, route or outcome assessment; some patients reported neuropsychiatric, dermatologic and gastrointestinal adverse effects.
From the source
Read at newsnationnow.com‘Wolverine’ peptide claims to accelerate healing and recovery
( NewsNation ) — In the Marvel “X-Men” franchise, Wolverine heals from major injuries at supernatural speed. An experimental peptide claims it provides the same superhero-style capabilities.